EBR Systems secures Priority Review from Australia's TGA for its wireless cardiac pacing system, fast-tracking regulatory approval and expanding access for heart failure patients. This follows strong US commercial momentum after FDA approval.
- TGA grants Priority Review for WiSE System
- Accelerated ARTG inclusion pathway shortens review period
- WiSE offers leadless CRT option for heart failure patients
- EBR plans imminent ARTG application submission
- Builds on FDA approval and growing US commercial activity
TGA Priority Review Accelerates WiSE System Approval
EBR Systems (ASX:EBR) has achieved a crucial regulatory milestone with the Therapeutic Goods Administration (TGA) granting Priority Review Determination for its WiSE wireless cardiac resynchronisation therapy (CRT) system. This designation significantly shortens the evaluation timeframe from the usual 225 working days to approximately 150, aiming to hasten the device's inclusion on the Australian Register of Therapeutic Goods (ARTG).
The Priority Review pathway targets breakthrough medical devices addressing serious conditions with unmet clinical needs. For EBR, this means a faster route to market in Australia, complementing its existing US commercial launch following FDA approval in April 2025. The WiSE System is designed to provide a leadless pacing solution for heart failure patients who cannot benefit from conventional CRT, potentially reducing complications associated with traditional leads.
Building on US Commercial Momentum and Clinical Validation
EBR’s CEO John McCutcheon highlighted the strategic importance of this regulatory progress, noting that the Priority Review reflects the WiSE System’s potential to fill a significant treatment gap in Australia. This move follows a period of rapid commercial expansion in the US, where EBR more than doubled WiSE implants in Q1 2026, generating preliminary revenue between US$2.25 million and US$2.36 million. The company also signed 16 new purchase agreements and trained 22 physicians during that quarter, underscoring growing clinical adoption and market traction.
This commercial momentum in the US, detailed in recent reporting, provides a strong foundation for Australian market entry and supports the company’s near-term plan to submit its ARTG application. Inclusion on the ARTG will be critical to enabling earlier patient access to this novel leadless CRT technology within Australia’s healthcare system.
Implications for Heart Failure Treatment Options
The WiSE System represents a distinct departure from conventional CRT devices by eliminating the need for coronary sinus leads to stimulate the left ventricle. This innovation targets patients who have limited or no options with traditional lead-based therapies, potentially improving outcomes and reducing device-related complications.
While the exact timing of ARTG inclusion and subsequent commercial launch in Australia remains uncertain, the Priority Review status positions EBR well to accelerate access. However, broader adoption will depend on factors such as reimbursement pathways and clinician acceptance, areas where further developments are anticipated.
As EBR navigates this regulatory and commercial expansion, the company’s progress will be closely watched by investors and healthcare providers alike, particularly given the evolving landscape of cardiac rhythm management technologies.
Bottom Line?
EBR’s TGA Priority Review fast-tracks Australian market access but commercial success hinges on timely ARTG inclusion and healthcare adoption.
Questions in the middle?
- How quickly will EBR submit and secure ARTG inclusion following Priority Review?
- What reimbursement frameworks will support WiSE adoption in Australia?
- Can WiSE’s leadless CRT technology gain traction against established therapies?